AlphAIAlphAI — Financial news for AI agents
investing.comSEP 172 min read$OSCR

Piper Sandler raises Oscar Health stock price target on ACA growth

Piper Sandler raised its price target for Oscar Health (OSCR) to $48, citing ACA growth and a 12x multiple on 2030 earnings. The stock has surged 139% in six months, with analysts predicting profitability this year. Oscar Health reported strong Q2 2026 results, exceeding earnings and revenue expectations, and raised its 2026 guidance.

Original reporting
investing.com
Published Sep 17, 2026, 12:31 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 17, 2026, 1:34 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$OSCR
Bullish
high confidence
Mentioned
$OSCR
Relevance
6/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$OSCRBullishMed
01

Why it matters

The earnings beat and target raise could drive short-term buying pressure.

02

Market read

Oscar Health's earnings beat and upgraded targets provide a fresh catalyst for traders.

03

What to watch

Potential regulatory changes to ACA could affect future earnings.

Relevance 6/10Novelty 6/10Timing: published today

Background

Oscar Health reported stronger-than-expected Q2 2026 results and received an analyst price target increase.

Company-level read

Ticker impact

$OSCRBullishHigh confidence
Context

Piper Sandler raised OSCR price target to $48 and reported Q2 2026 earnings beat with $1.10 EPS and higher revenue.

Expected impact

Potential rally toward the new $48 target.

Evidence & confidence

Target raise and earnings beat provide a clear catalyst for price appreciation.

Market effects

Sector

Positive signal for health insurance and ACA-related stocks.

Regional

U.S. market focus on health insurers.

Global

Limited to U.S. healthcare sector.

Counterpoint

What could challenge this read

Target may be overly optimistic if ACA enrollment growth slows.

Key entities

  • Analyst
    Piper Sandler

    Raised price target to $48, Overweight rating.

  • Analyst
    BofA Securities

    Raised price target to $30, Underperform rating.

Read at source← All news

Related articles

SEP 16
$OSCRHighAI 8/10

OSCR Looks 33.9% Overvalued on GF Value™ as Oscar Health Revises

Oscar Health (OSCR) revised its 2026 forecasts, raising operating earnings outlook by $100M to $600M-$800M and improving medical loss ratio guidance. Revenue guidance remains $18.7B-$19B. GF Value™ indicates OSCR is 33.9% overvalued at $32.44. The company has a strong GF Score™ of 83/100, with high growth and momentum ratings but middling profitability and valuation. Insiders have sold significantly more shares than they've bought.

gurufocus.com2 min
SEP 16
$OSCRHighAI 8/10

Oscar Health boosts 2026 earnings outlook, affirms revenue

Oscar Health (OSCR) updated its 2026 earnings outlook, lowering its Medical Loss Ratio to 81.0%-82.0% and raising earnings from operations to $600M-$800M. The company reaffirmed revenue guidance of $18.7B-$19.0B and maintained SG&A expense ratio targets. The updates will be discussed at its 2026 Investor Day on September 16, 2026.

tipranks.com2 min
SEP 16
$OSCRHighAI 8/10

Oscar Health raises FY26 earnings guidance by $100 million

Oscar Health (OSCR) raised its 2026 earnings guidance by $100 million, citing improved cost controls. The company expects earnings from operations to range from $600 million to $800 million, with a medical loss ratio of 81.0% to 82.0%. Total revenue guidance remains unchanged at $18.7 billion to $19.0 billion. The stock has gained 85.57% over the past year, reaching a 52-week high of $27.59.

scanx.trade2 min
SEP 5
$CNCMed

CNC, OSCR Stocks Rally After Baird Calls Risk Adjustment Results Favorable

Centene (CNC) and Oscar Health (OSCR) shares rose 6% and 12% respectively after Baird reported favorable risk adjustment results. Baird noted the outcomes support Centene's Q4 commentary and align with Oscar's June investor conference remarks. Molina (MOH) shares also rose 2% despite a minor negative impact. The Centers for Medicare & Medicaid Services released final 2025 risk adjustment data on June 30, affecting insurers' earnings.

stocktwits.com2 min